Last reviewed · How we verify
NCT03401840: STEREOPOSTOP
STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03
NA trial testing postoperative hypofractionated stereotactic radiotherapy in Head and Neck Neoplasms in 90 participants. Completed in 28 September 2023.
28 September 2023
Quick facts
| Lead sponsor | Centre Jean Perrin |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 23 January 2018 |
| Primary completion | 28 September 2023 |
| Estimated completion | 28 September 2023 |
| Sites | 24 locations across France |
Drugs / interventions tested
- postoperative hypofractionated stereotactic radiotherapy
Conditions studied
- Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →
Sponsor
Centre Jean Perrin — full company profile →
Who can join
18 and older, any sex, with Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this national, open-label, non-randomized phase II trial is to evaluate severe late toxicity of postoperative hypofractionated stereotactic radiotherapy (SBRT) in the treatment of early stage oropharyngeal and oral cavity cancer with high risk margins.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J, Thivat E, Millardet C, Saroul N, et al · · 2020 · cited 14× · PMID 32758188 · DOI 10.1186/s12885-020-07231-3 -
The Evolving Role of Stereotactic Body Radiation Therapy for Head and Neck Cancer: Where Do We Stand?
Mohamad I, Karam I, El-Sehemy A, Abu-Gheida I, et al · · 2023 · cited 9× · PMID 37894377 · DOI 10.3390/cancers15205010 -
HYPORT: Phase 1 Study of 3-Week Hypofractionated Postoperative Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
Moon DH, Avkshtol V, Vo D, Ahn C, et al · · 2024 · cited 3× · PMID 37380084 · DOI 10.1016/j.ijrobp.2023.06.010 -
Stereotactic ablative radiotherapy for treating primary head and neck cancer and locoregional recurrence: A comprehensive review of the literature.
Franzese C, Balermpas P. · · 2024 · cited 2× · PMID 38590327 · DOI 10.1016/j.ctro.2024.100766 -
Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial.
Biau J, Sun X, Liem X, Faivre JC, et al · · 2025 · cited 1× · PMID 41632122 · DOI 10.1001/jamanetworkopen.2025.49975 -
Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2
Biau J, Lopez L, Thivat E, Casile M, et al · · 2023 · PMID 36466746 · DOI 10.1016/j.ctro.2022.11.007
Verify or expand the search:
- PubMed search for NCT03401840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of postoperative hypofractionated stereotactic radiotherapy
Trials testing the same drug.
- NCT05124236 — Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases · NA · recruiting
Other recruiting trials for Head and Neck Neoplasms
Currently open trials in the same condition.
- NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
- NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
- NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting
Other Centre Jean Perrin trials
Trials by the same sponsor.
- NCT07361471 — Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovari · NA · recruiting
- NCT06512558 — Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery · NA · recruiting
- NCT06600802 — Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA- · NA · recruiting
- NCT05433077 — Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment · active not recruiting
- NCT05157594 — hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03401840 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Jean Perrin
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03401840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing